Market capitalization | $44.07m |
Enterprise Value | $19.44m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.53 |
P/S ratio (TTM) P/S ratio | 5.75 |
P/B ratio (TTM) P/B ratio | 1.83 |
Sales growth (TTM) Sales growth | 1,282.40% |
Turnover (TTM) Turnover | $7.67m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
1 Analyst has issued a forecast Lipocine, Inc.:
1 Analyst has issued a forecast Lipocine, Inc.:
Mar '24 |
+/-
%
|
||
Turnover | 7.67 7.67 |
1,295%
1,295%
|
|
Gross income | 7.64 7.64 |
1,315%
1,315%
|
|
EBITDA | -7.38 -7.38 |
45%
45%
|
EBIT (operating result) EBIT | -7.41 -7.41 |
44%
44%
|
Net profit | -8.97 -8.97 |
19%
19%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.
Head office | United States |
CEO | Mahesh Patel |
Employees | 17 |
Founded | 2011 |
Website | www.lipocine.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.